Quintiles & IMS Health Announce Global Collaboration to Advance the Use of Next-Generation Real-World Evidence in Late-Stage ...
October 22 2015 - 6:45AM
Business Wire
Network of complementary data sources,
innovative technologies, scientific expertise to generate insights
faster and demonstrate value to healthcare stakeholders
Quintiles and IMS Health today announced a global strategic
alliance that will advance the way biopharmaceutical companies
generate real-world evidence (RWE) and apply critical insights to
drive late-stage clinical research. With complementary strengths in
real-world data management, operational delivery, advanced
analytics, and scientific and therapeutic expertise, the
collaboration will accelerate assessments of treatment impact and
help improve patient outcomes.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20151022005287/en/
As healthcare stakeholders increase their focus on value,
evidence of a medicine’s effectiveness and safety in real-world
settings continues to be a critical component of drug development
and healthcare delivery. This alliance brings together
market-leading capabilities in prospective and retrospective
research, operational study delivery, proprietary RWE technologies
and epidemiological expertise to provide customers with a complete
view of a product’s impact and the patient experience in clinical
practice.
“As demand increases for real-world evidence, biopharmaceutical
companies need to integrate data from multiple sources to
accelerate critical insights for stakeholders,” said Scott
Evangelista, president, Integrated Healthcare Services at
Quintiles. “This collaboration greatly enhances access to
healthcare data from across the world – providing customers with
the critical information and the related services needed to
demonstrate the value of their medicines to physicians, payers and
patients.”
The alliance will combine IMS Health’s strength in
technology-enabled RWE information management, deep understanding
of global health systems and advanced clinical and commercial
analytics with Quintiles’ global breadth of operational expertise,
experience in prospective studies and scientific knowledge to
support all aspects of real-world and late-phase research.
Healthcare stakeholders will benefit from IMS Health’s access to
500+ million anonymous patient records, as well as its scalable
Evidence 360 RWE platform. Quintiles is providing experience in
real-world and late-phase programs involving more than 74,000 sites
and more than 650,000 enrolled patients in more than 100 countries
since 2011 along with its award-winning Quintiles Infosario®
platform. Applying these combined strengths will enable
biopharmaceutical companies to optimize physician and patient
recruitment, streamline data collection and study execution, as
well as improve the quality and impact of real-world evidence
worldwide.
“We are excited to offer an improved method for generating
healthcare evidence that addresses a long-standing need for more
robust information, greater insight on disease and treatment
impact, and more cost-effective data collection,” said Jon Resnick,
vice president and general manager, Real-World Evidence Solutions
at IMS Health. “Through this collaboration, we will help
improve the body of information healthcare stakeholders can access
and use – informing better decisions that benefit patients and the
entire health delivery system.”
About Quintiles
Quintiles (NYSE:Q) helps biopharma and other healthcare
companies improve their probability of success by connecting
insights from our deep scientific, therapeutic and analytics
expertise with superior delivery for better outcomes. From advisory
through operations, Quintiles is the world’s largest provider of
product development and integrated healthcare services, including
commercial and observational solutions. Conducting operations in
approximately 100 countries, Quintiles is a member of the FORTUNE
500 and has been named to FORTUNE’s list of the “World’s Most
Admired Companies.” To learn more, visit www.quintiles.com.
About IMS Health
IMS Health (NYSE:IMS) is a leading global information and
technology services company providing clients in the healthcare
industry with end-to-end solutions to measure and improve their
performance. Our 7,500 services experts connect configurable SaaS
applications to 10+ petabytes of complex healthcare data in the IMS
One™ cloud platform, delivering unique insights into diseases,
treatments, costs and outcomes. The company’s 15,000 employees
blend global consistency and local market knowledge across 100
countries to help clients run their operations more efficiently.
Customers include pharmaceutical, consumer health and medical
device manufacturers and distributors, providers, payers,
government agencies, policymakers, researchers and the financial
community.
As a global leader in protecting individual patient privacy, IMS
Health uses anonymous healthcare data to deliver critical,
real-world disease and treatment insights. These insights help
biotech and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders to
identify unmet treatment needs and understand the effectiveness and
value of pharmaceutical products in improving overall health
outcomes. Additional information is available at www.imshealth.com.
Click here to subscribe to Mobile Alerts for
Quintiles.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151022005287/en/
Quintiles Media RelationsPhil Bridges,
+1-919-998-1653phil.bridges@quintiles.comorQuintiles Investor
RelationsTodd Kasper,
+1-919-998-2590InvestorRelations@quintiles.comorIMS Health Media
RelationsTor Constantino,
+1-484-567-6732tconstantino@us.imshealth.comorIMS Health Investor
RelationsTom Kinsley, +1-203-448-4691tkinsley@imshealth.com
IMS HEALTH HOLDINGS, INC. (NYSE:IMS)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMS HEALTH HOLDINGS, INC. (NYSE:IMS)
Historical Stock Chart
From Jul 2023 to Jul 2024